LigaChem Biosciences, Inc.
16
3
4
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
2 terminated/withdrawn out of 16 trials
81.8%
-4.7% vs industry average
0%
0 trials in Phase 3/4
22%
2 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
Role: lead
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Role: collaborator
PanACEA - STEP2C -01
Role: collaborator
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Role: lead
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Role: lead
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
Role: lead
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
Role: lead
Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
Role: lead
A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace
Role: lead
A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
Role: lead
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers
Role: lead
An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371
Role: lead
To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371
Role: lead
Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371
Role: lead
Multiple Ascending Dose Study for LCB01-0371
Role: lead
A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study
Role: lead
All 16 trials loaded